Goldman Sachs Group Inc Vectiv Bio Holding Ag Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2023 May 14, 2024	BUY	$8.29 - $16.97 $9.09 Million - $18.6 Million	1,096,570 Added 4049.82%	1,123,647 $19 Million
Q2 2023 Aug 14, 2023	BUY	$8.29 - $16.97 $9.09 Million - $18.6 Million	1,096,570 Added 4049.82%	1,123,647 $19 Million
Q1 2023 May 14, 2024	BUY	$7.34 - $9.15 $198,745 - $247,754	27,077 New	27,077 $230,000
Q1 2023 May 11, 2023	BUY	$7.34 - $9.15 $198,745 - $247,754	27,077 New	27,077 $230,000

Others Institutions Holding VECT

# of Institutions

1

Shares Held

510K

Call Options Held

0

Put Options Held

0

Regency Capital Management Inc.\De

510K
Shares

$0
0.0% of portfolio

About VectivBio Holding AG

Ticker VECT
Exchange NASDAQ
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...

More about VECT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.